(Reuters) -GSK will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson’s hepatitis B therapy, the British drugmaker said on Tuesday. JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018. Exclusive rights to the therapy will fuel the expansion of GSK’s own…
By Chibuike Oguh NEW YORK (Reuters) -Shares of Nvidia Corp dropped by about 5% to a near five-month low on Tuesday following a Wall Street Journal report that the artificial intelligence (AI) giant may be forced to cancel up to $5 billion worth of advanced chip orders to China in compliance with new U.S. government…
By Ron Bousso and Shadia Nasralla LONDON (Reuters) – BP on Tuesday reported third-quarter earnings of $3.3 billion, missing analysts’ forecasts due to weak gas trading results while the firm wrote down a large chunk of a U.S. offshore wind project. BP shares were 4.3% lower by 1325 GMT after the results fell well short…
By Deena Beasley (Reuters) -Amgen on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition this month of Horizon Therapeutics and its shares fell nearly 4%. Sales of some high profile medicines also fell short of expectations, likely contributing to the share move….
By Stephen Nellis SAN FRANCISCO (Reuters) -Apple on Monday introduced new MacBook Pro and iMac computers and three new chips to power them, with the company saying it had redesigned its graphics processing units (GPU), a key part of the chip where Nvidia dominates the market. The new computers and the M3, M3 Pro and…
